Table IV.
Univariate analysis of progression-free survival.
| Univariate analysis | ||
|---|---|---|
| Factor | Hazard ratio (95% CI) | P-value |
| Age (≥62 years vs. <62 years) | 0.822 (0.355–1.906) | 0.648 |
| Concurrent chemotherapy (no vs. yes) | 0.463 (0.200–1.070) | 0.072 |
| FIGO stage (I+II vs. III+IV) | 4.264 (1.664–10.927) | 0.003 |
| PeLN (positive vs. negative) | 0.318 (0.124–0.816) | 0.017 |
| PALN (positive vs. negative) | 0.293 (0.098–0.874) | 0.280 |
| CD8+ TILs (pre-RT) (low vs. high) | 0.302 (0.102–0.894) | 0.031 |
| CD8+ TILs (post-10 Gy) (low vs. high) | 0.368 (0.150–0.905) | 0.030 |
PeLN, lymph node metastasis in pelvis; PALN, para-aortic lymph node metastasis; RT, radiotherapy; TIL, tumor-infiltrating lymphocyte; FIGO, International Federation of Gynecology and Obstetrics.